SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate upcoming earnings, with the community actively discussing potential surprises and raised guidance. Bullish sentiment is high, and many are holding positions, while some anticipate a post-earnings sell-off, a pattern observed in previous quarters. Discussions also include long-term growth potential, S&P 500 inclusion, and the impact of potential interest rate cuts.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph ($HBAR) is trending amid anticipation of a spot ETF approval and discussions around its potential impact. The community is actively discussing potential price targets and the broader implications of institutional investment. Some investors view it as a promising alternative within the crypto space, while others urge caution until clearer regulations are in place.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending amid ongoing discussions around AI, cloud services, and quantum computing, with the community weighing the potential impact of new technologies and partnerships. Some traders are taking profits after a recent run-up, while others remain bullish, citing the company's strong position in multiple sectors and potential for future growth. Upcoming earnings are a key point of focus, with many anticipating a positive catalyst for the stock.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Recent news and analyst upgrades have fueled bullish sentiment around GOOGL, particularly regarding its AI initiatives and cloud services. The community is actively discussing potential upside, with some anticipating new all-time highs and a price target of $300+ after upcoming earnings. However, some traders are cautious, noting technical resistance and expressing concerns about short-term pullbacks amid broader market volatility.

Galaxy Digital, Inc. engages in digital assets and data center infrastructure, delivering solutions that accelerate progress in finance and artificial intelligence. It operates through the following segments: Digital Assets and Data Centers. The digital assets segment offers institutional access to trading, advisory, asset management, staking, self-custody, and tokenization technology. The Data Centers segment competes with a range of infrastructure providers that are building or repurposing facilities to support the rapidly growing demand for AI and compute-intensive workloads. The company was founded by Michael Novogratz in 2018 and is headquartered in New York, NY.

Galaxy Digital Inc. - Ordinary Shares - Class A

GLXY is trending downwards after announcing a private offering of exchangeable senior notes, leading to community debate on whether this is a strategic move for growth or a dilution trap. While some investors see it as a means to finance data center expansion and AI initiatives, others express concerns about the timing and potential impact on the stock price. The community is closely watching for further news and developments to gauge the long-term implications.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics ($NTLA) is trending due to a temporary halt in patient dosing for two late-stage trials after a participant experienced liver injury, causing a significant stock decline. The community is actively discussing the implications of this setback, including potential delays and the possibility of positive catalysts, while Ark Invest's recent purchase adds a layer of intrigue. Some traders believe the selloff is an overreaction and are anticipating a price bounce.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group (UNH) is trending as investors discuss its upcoming earnings report and potential market impact, especially given mixed sector signals from peers like ELV and MOH. Community members are weighing factors like premium adjustments, the Optum division's performance, and broader healthcare industry trends, with some anticipating a significant move post-earnings. Speculation includes possible government actions affecting healthcare and potential shifts in investor sentiment.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending amid news of its expansion into the AI data center market with new AI200 and AI250 chips, positioning it as a competitor to Nvidia and AMD; the community is actively discussing the potential impact of this shift and comparing Qualcomm's fundamentals and valuation to its peers. Traders are weighing whether Qualcomm's AI ambitions justify the recent rally, while also noting Rosenblatt's bullish note on its AI data center ambitions, with some seeing a buying opportunity due to its lower P/E ratio compared to competitors.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond ($BBBY) is trending as the community discusses its potential, particularly its ties to blockchain through Tzero, while drawing comparisons to meme stock favorite, Gamestock ($GME).  Recent news includes a new ticker and speculation on strategic partnerships, while traders debate the company's direction and potential for a turnaround.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Token is trending with community members actively discussing its price action and potential, with some expressing frustration over its lack of movement despite positive news and others remaining optimistic about its long-term utility and potential integration with stablecoins and payment systems; many mention its association with Flexa, while some are concerned about tokenomics and management.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

@BioAmerica 
$CVM BULLISH
You talk as one of those that would love for our country to be taken over by government and corrupt agencies. Just remove all the competition in the market. Allow big pharma to control all medicines and tell us they can manufacture monopolized medicine and push down our throats they can’t be held accountable for any health issues for the next 75 years. Do away with the little guy. Sell the small farms to China.
       Who are the owners of the chemotherapy and radiation sells and post surgery medicines for these patients and possibly future patients of different kinds of cancer.
I would say you were naive but I don’t think that is the case in listening to your investing strategy in CVM. I think you are just like the FDA and big pharma, not thinking of life or quality life for those future patients of head and neck cancer and your bragging about being on numberous other boards like this one those sicknesses either. Just like I said Money Rules even over life.

@cruiser24  
 
&quot;Enrollment was already complete (928 patients) by September 2016, so the hold primarily affected ongoing treatments and follow-up processes, but patients could continue at physicians’ discretion initially.&quot; 
 
You continue to ignore the fact that the company attempted to add additional patients to the clinical trial but withdrew that request after the FDA told them NO.   
Why did they want to add more patients?  Why did the FDA tell them no?   
 
Trying to use AI to write your posts for you again?  Is that why they look like cut and paste gibberish?   
 
You are right.  Money rules everything.  And it is ashamed that this company has been allowed to spend 100&#39;s of millions of dollars to try to get Multikine approved when any reasonable person realizes that if they had just sold the drug to a major pharma company years ago, it might be long approved by now.   
 
So, who is has gotten rich over all of these years?

StockTwits Web

Bio Trader

StockTwits for iOS

Cel-Sci Corp.

 BULLISH
You talk as one of those that would love for our country to be taken over by government and corrupt agencies. Just remove all the competition in the market. Allow big pharma to control all medicines and tell us they can manufacture monopolized medicine and push down our throats they can’t be held accountable for any health issues for the next 75 years. Do away with the little guy. Sell the small farms to China.
       Who are the owners of the chemotherapy and radiation sells and post surgery medicines for these patients and possibly future patients of different kinds of cancer.
I would say you were naive but I don’t think that is the case in listening to your investing strategy in CVM. I think you are just like the FDA and big pharma, not thinking of life or quality life for those future patients of head and neck cancer and your bragging about being on numberous other boards like this one those sicknesses either. Just like I said Money Rules even over life.

Randy Hart

@cruiser24 @BioAmerica @BioAmerica Poor old man is truly in over his head.

StockTwits For Android 

Dan Schneider

@BioGLovesMe @BioAmerica 
@cruiser24 
$CVM BULLISH
Speaking of over your head. How did you manage to get out of that commode?Must have been rough. It took you all day.
GLTA-BULLS
POAY-bears
One day closer.

 BULLISH
Speaking of over your head. How did you manage to get out of that commode?Must have been rough. It took you all day.
GLTA-BULLS
POAY-bears
One day closer.